ZyVersa Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020
Net Income	-24.95	-9.41	-98.3	-14.12	-8.08	Upgrade
Depreciation & Amortization	-	0.01	0.01	0.01	0.01	Upgrade
Other Amortization	0.06	-	-	0.04	0.32	Upgrade
Asset Writedown & Restructuring Costs	18.65	-	93.33	-	-	Upgrade
Stock-Based Compensation	0.22	0.71	1.19	3.58	4.14	Upgrade
Other Operating Activities	-0.61	0.21	-7.56	-0.05	-0.44	Upgrade
Change in Accounts Payable	0.69	0.89	2.41	4.54	-0.31	Upgrade
Change in Other Net Operating Assets	0.83	0.08	0.19	1.12	-0.71	Upgrade
Operating Cash Flow	-5.11	-7.52	-8.72	-4.89	-5.08	Upgrade
Long-Term Debt Issued	-	-	-	-	5.23	Upgrade
Net Debt Issued (Repaid)	-	-	-	-	5.23	Upgrade
Issuance of Common Stock	2.05	6.54	19.08	-	-	Upgrade
Repurchase of Common Stock	-	-	-0.01	-	-	Upgrade
Other Financing Activities	1.63	-0.63	-2.42	-0.1	-	Upgrade
Financing Cash Flow	3.69	5.91	5.96	1.87	5.23	Upgrade
Net Cash Flow	-1.43	-1.61	-2.76	-3.02	0.15	Upgrade
Levered Free Cash Flow	-2.88	-4.09	-5.46	-1.65	-2.02	Upgrade
Unlevered Free Cash Flow	-2.56	-3.92	-5.46	-1.43	-1.83	Upgrade
Change in Working Capital	1.52	0.97	2.6	5.66	-1.02	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.